Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6688979rdf:typepubmed:Citationlld:pubmed
pubmed-article:6688979lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:6688979lifeskim:mentionsumls-concept:C0391978lld:lifeskim
pubmed-article:6688979lifeskim:mentionsumls-concept:C0032950lld:lifeskim
pubmed-article:6688979lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:6688979lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:6688979pubmed:issue181lld:pubmed
pubmed-article:6688979pubmed:dateCreated1984-1-26lld:pubmed
pubmed-article:6688979pubmed:abstractTextAdult male rats were treated for six weeks by prednisolone and/or 1,25-(OH)2D3 and given a diet containing either 0.5% calcium or 0.01% Ca and 0.6% phosphorus. Both prednisolone administration and a low-Ca diet were associated with a lower bone mass than that observed in control rats given a 0.5% Ca diet. The percentage of osteoid surface was decreased in rats given prednisolone; these rats also had a lower osteoclast number. The results were consistent with a lower bone turnover during prednisolone treatment. Administration of 1,25-(OH)2D3, resulting in a slightly higher mean level of 1,25-(OH)2D3 in serum, had a positive effect on bone mass, which may be related to increased osteoblastic activity; no increase in the osteoclast number occurred.lld:pubmed
pubmed-article:6688979pubmed:languageenglld:pubmed
pubmed-article:6688979pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6688979pubmed:citationSubsetAIMlld:pubmed
pubmed-article:6688979pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6688979pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6688979pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6688979pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6688979pubmed:statusMEDLINElld:pubmed
pubmed-article:6688979pubmed:monthDeclld:pubmed
pubmed-article:6688979pubmed:issn0009-921Xlld:pubmed
pubmed-article:6688979pubmed:authorpubmed-author:DeLucaH FHFlld:pubmed
pubmed-article:6688979pubmed:authorpubmed-author:LindgrenJ UJUlld:pubmed
pubmed-article:6688979pubmed:authorpubmed-author:JohnellOOlld:pubmed
pubmed-article:6688979pubmed:issnTypePrintlld:pubmed
pubmed-article:6688979pubmed:ownerNLMlld:pubmed
pubmed-article:6688979pubmed:authorsCompleteYlld:pubmed
pubmed-article:6688979pubmed:pagination264-8lld:pubmed
pubmed-article:6688979pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6688979pubmed:meshHeadingpubmed-meshheading:6688979-...lld:pubmed
pubmed-article:6688979pubmed:meshHeadingpubmed-meshheading:6688979-...lld:pubmed
pubmed-article:6688979pubmed:meshHeadingpubmed-meshheading:6688979-...lld:pubmed
pubmed-article:6688979pubmed:meshHeadingpubmed-meshheading:6688979-...lld:pubmed
pubmed-article:6688979pubmed:meshHeadingpubmed-meshheading:6688979-...lld:pubmed
pubmed-article:6688979pubmed:meshHeadingpubmed-meshheading:6688979-...lld:pubmed
pubmed-article:6688979pubmed:meshHeadingpubmed-meshheading:6688979-...lld:pubmed
pubmed-article:6688979pubmed:meshHeadingpubmed-meshheading:6688979-...lld:pubmed
pubmed-article:6688979pubmed:meshHeadingpubmed-meshheading:6688979-...lld:pubmed
pubmed-article:6688979pubmed:meshHeadingpubmed-meshheading:6688979-...lld:pubmed
pubmed-article:6688979pubmed:meshHeadingpubmed-meshheading:6688979-...lld:pubmed
pubmed-article:6688979pubmed:meshHeadingpubmed-meshheading:6688979-...lld:pubmed
pubmed-article:6688979pubmed:meshHeadingpubmed-meshheading:6688979-...lld:pubmed
pubmed-article:6688979pubmed:year1983lld:pubmed
pubmed-article:6688979pubmed:articleTitleStudies of bone tissue in rats treated by prednisolone and 1,25-(OH)2D3.lld:pubmed
pubmed-article:6688979pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6688979pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6688979lld:pubmed